A systematic review and meta-analysis of 130,000 individuals shows smoking does not modify the association of APOE genotype on risk of coronary heart disease

Atherosclerosis

Volumn 237, Issue 1, 2014, Pages 5-12

  Holmes, Michael V ^a,b   Frikke Schmidt, Ruth ^c,e,f   Melis, Daniela ^b   Luben, Robert ^g   Asselbergs, Folkert W ^b,h,i   Boer, Jolanda M A ^j   Cooper, Jackie ^b   Palmen, Jutta ^b   Horvat, Pia ^b   Engmann, Jorgen ^b   Li, Ka Wah ^b   Onland Moret, N Charlotte ^h   Hofker, Marten H ^k   Kumari, Meena ^b   Keating, Brendan J ^a   Hubacek, Jaroslav A ^l   Adamkova, Vera ^l   Kubinova, Ruzena ^m   Bobak, Martin ^b   Khaw, Kay Tee ^g   Nordestgaard, Børge G ^d,e,f   Wareham, Nick ^e   Humphries, Steve E ^b   Langenberg, Claudia ^b,g   Tybjaerg Hansen, Anne ^c,d,e,f   Talmud, Philippa J ^b   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^d FREDERIKSBERG HOSPITAL   (Denmark)

^e The Copenhagen General Population Study Herlev Hospital Copenhagen University Hospital ^*  (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^j NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^k UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^l INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^m NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

more..

Author keywords

APOE genotype; Coronary heart disease; Gene environment interaction; Smoking

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; CARRIER PROTEIN;

ALLELE; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY SURGERY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SYSTEMATIC REVIEW; ADULT; ADVERSE EFFECTS; AGED; COHORT ANALYSIS; CORONARY ARTERY DISEASE; FEMALE; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HETEROZYGOTE; MALE; META ANALYSIS; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; ALLELES; APOLIPOPROTEIN E4; COHORT STUDIES; CORONARY DISEASE; FEMALE; GENE-ENVIRONMENT INTERACTION; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SMOKING;

EID: 84907695230     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.07.038     Document Type: Article

References (30)

1. Lim S.S., Vos T., Flaxman A.D., Danaei G., Shibuya K., Adair-Rohani H., et al. Acomparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2224-2260.
2. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240(4852):622-630.
3. Angelopoulos T.J., Lowndes J. ApoE genotype: impact on health, fitness and nutrition. World Rev Nutr Diet 2008, 98:77-93.
4. Bennet A.M., Di Angelantonio E., Ye Z., Wensley F., Dahlin A., Ahlbom A., et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007, 298(11):1300-1311.
5. Strittmatter W.J., Bova Hill C. Molecular biology of apolipoprotein E. Curr Opin Lipidol 2002, 13(2):119-123.
6. Humphries S.E., Talmud P.J., Hawe E., Bolla M., Day I.N., Miller G.J. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet 2001, 358(9276):115-119.
7. Keavney B., Parish S., Palmer A., Clark S., Youngman L., Danesh J., et al. Large-scale evidence that the cardiotoxicity of smoking is not significantly modified by the apolipoprotein E 2/3/4 genotype. Lancet 2003, 361(9355):396-398.
8. Grammer T.B., Hoffmann M.M., Scharnagl H., Kleber M.E., Silbernagel G., Pilz S., et al. Smoking, apolipoprotein E genotypes, and mortality (the Ludwigshafen RIsk and Cardiovascular Health study). Eur Heart J 2013, 34(17):1298-1305.
9. Gustavsson J., Mehlig K., Leander K., Strandhagen E., Bjorck L., Thelle D.S., et al. Interaction of apolipoprotein E genotype with smoking and physical inactivity on coronary heart disease risk in men and women. Atherosclerosis 2012, 220(2):486-492.
10. Jolivalt C., Leininger-Muller B., Bertrand P., Herber R., Christen Y., Siest G. Differential oxidation of apolipoprotein E isoforms and interaction with phospholipids. Free Radic Biol Med 2000, 28(1):129-140.
11. Myung S.K., Ju W., Cho B., Oh S.W., Park S.M., Koo B.K., et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2013, 346:f10.
12. Moher D., Liberati A., Tetzlaff J., Altman D.G., Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6(7):e1000097.
13. Meade T.W., Wilkes H.C., Stirling Y., Brennan P.J., Kelleher C., Browne W. Randomized controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: design and pilot study. Eur Heart J 1988, 9(8):836-843.
14. Beulens J.W., Monninkhof E.M., Verschuren W.M., van der Schouw Y.T., Smit J., Ocke M.C., et al. Cohort profile: the EPIC-NL study. Int J Epidemiol 2010, 39(5):1170-1178.
15. Netuveli G., Wiggins R.D., Hildon Z., Montgomery S.M., Blane D. Quality of life at older ages: evidence from the English longitudinal study of aging (wave 1). JEpidemiol Commun Health 2006, 60(4):357-363.
16. Nordestgaard B.G., Agerholm-Larsen B., Wittrup H.H., Tybjaerg-Hansen A. Aprospective cardiovascular population study used in genetic epidemiology. The Copenhagen City Heart Study. Scand J Clin Lab Invest Suppl. 1996, 226:65-71.
17. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298(3):299-308.
18. Cifkova R., Skodova Z., Bruthans J., Adamkova V., Jozifova M., Galovcova M., et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis 2010, 211(2):676-681.
19. Day N., Oakes S., Luben R., Khaw K.T., Bingham S., Welch A., et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999, 80(Suppl.1):95-103.
20. Peasey A., Bobak M., Kubinova R., Malyutina S., Pajak A., Tamosiunas A., et al. Determinants of cardiovascular disease and other non-communicable diseases in Central and Eastern Europe: rationale and design of the HAPIEE study. BMC Public Health 2006, 6:255.
21. Lussier-Cacan S., Bolduc A., Xhignesse M., Niyonsenga T., Sing C.F. Impact of alcohol intake on measures of lipid metabolism depends on context defined by gender, body mass index, cigarette smoking, and apolipoprotein E genotype. Arteriosclerosis Thromb Vascu Biol 2002, 22(5):824-831.
22. Chen X.H., Rodriguez S., Hawe E., Talmud P.J., Miller G.J., Underhill P., et al. Evidence of admixture from haplotyping in an epidemiological study of UK Caucasian males: implications for association analyses. Human Heredity 2004, 57(3):142-155.
23. Liu S., Ma J., Ridker P.M., Breslow J.L., Stampfer M.J. Aprospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. Atherosclerosis 2003, 166(2):323-329.
24. Talmud P.J., Lewis S.J., Hawe E., Martin S., Acharya J., Marmot M.G., et al. No APOE4 effect on coronary heart disease risk in a cohort with low smoking prevalence: The Whitehall II study. Atherosclerosis 2004, 177(1):105-112.
25. Yusuf S., Wittes J., Probstfield J., Tyroler H.A. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991, 266(1):93-98.
26. Hingorani A., Humphries S. Nature's randomised trials. Lancet 2005, 366(9501):1906-1908.
27. Sleight P. Debate: subgroup analyses in clinical trials: fun to look at - but don't believe them!. Curr Control Trials Cardiovasc Med 2000, 1(1):25-27.
28. Young N.S., Ioannidis J.P., Al-Ubaydli O. Why current publication practices may distort science. PLoS Med 2008, 5(10):e201.
29. Willke R.J., Zheng Z., Subedi P., Althin R., Mullins C.D. From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer. BMC Med Res Methodol 2012, 12:185.
30. Thrombosis prevention trial randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998, 351(9098):233-241.